牛牛AI助理已提取核心訊息
On January 25, 2024, HOOKIPA Pharma Inc., a clinical-stage biopharmaceutical company, received a notice from Roche indicating the termination of their Research Collaboration and License Agreement concerning the HB-700 cancer program, effective April 25, 2024. Despite meeting all criteria under the agreement, Roche exercised its right to terminate without cause. HOOKIPA will regain full rights to the HB-700 program and remains eligible for a milestone payment upon IND submission. Concurrently, HOOKIPA announced preliminary unaudited cash and cash equivalents of approximately $117.5 million as of December 31, 2023, with full financial details to be reported in the upcoming Annual Report. Additionally, the company is refocusing its strategy, prioritizing the clinical development of HB-200 for HPV16+ head and neck cancers and Gilead-partnered infectious disease programs. This strategic shift includes pausing development of HB-300 and most preclinical research, as well as a workforce reduction by 30%. The restructuring is expected to incur severance and related costs of approximately $1.5 million, with a non-cash impairment charge estimated between $10 million and $13 million due to the discontinuation of the GMP facility project.
On January 25, 2024, HOOKIPA Pharma Inc., a clinical-stage biopharmaceutical company, received a notice from Roche indicating the termination of their Research Collaboration and License Agreement concerning the HB-700 cancer program, effective April 25, 2024. Despite meeting all criteria under the agreement, Roche exercised its right to terminate without cause. HOOKIPA will regain full rights to the HB-700 program and remains eligible for a milestone payment upon IND submission. Concurrently, HOOKIPA announced preliminary unaudited cash and cash equivalents of approximately $117.5 million as of December 31, 2023, with full financial details to be reported in the upcoming Annual Report. Additionally, the company is refocusing its strategy, prioritizing the clinical development of HB-200 for HPV16+ head and neck cancers and Gilead-partnered infectious disease programs. This strategic shift includes pausing development of HB-300 and most preclinical research, as well as a workforce reduction by 30%. The restructuring is expected to incur severance and related costs of approximately $1.5 million, with a non-cash impairment charge estimated between $10 million and $13 million due to the discontinuation of the GMP facility project.
2024年1月25日，處於臨床階段的生物製藥公司HOOKIPA Pharma Inc. 收到羅氏的通知，表示其有關 HB-700 癌症計劃的研究合作和許可協議將終止，該協議自2024年4月25日起生效。儘管符合協議的所有標準，羅氏還是無故行使了終止協議的權利。HOOKIPA 將重新獲得 HB-700 計劃的全部權利，並在 IND 提交後仍有資格獲得里程碑式的付款。同時，HOOKIPA公佈了截至2023年12月31日的未經審計的初步現金及現金等價物約爲1.175億美元，完整的財務細節將在即將發佈的年度報告中公佈。此外，該公司正在重新調整其戰略重點，優先開發針對HPV16+頭頸癌的 HB-200 和吉利德合作的傳染病項目。這種戰略轉變包括暫停 HB-300 和大多數臨床前研究的開發，以及裁員 30%。重組預計將產生約150萬美元的遣散費和相關費用，由於GMP設施項目的終止，非現金減值費用估計在1000萬至1300萬美元之間。
2024年1月25日，處於臨床階段的生物製藥公司HOOKIPA Pharma Inc. 收到羅氏的通知，表示其有關 HB-700 癌症計劃的研究合作和許可協議將終止，該協議自2024年4月25日起生效。儘管符合協議的所有標準，羅氏還是無故行使了終止協議的權利。HOOKIPA 將重新獲得 HB-700 計劃的全部權利，並在 IND 提交後仍有資格獲得里程碑式的付款。同時，HOOKIPA公佈了截至2023年12月31日的未經審計的初步現金及現金等價物約爲1.175億美元，完整的財務細節將在即將發佈的年度報告中公佈。此外，該公司正在重新調整其戰略重點，優先開發針對HPV16+頭頸癌的 HB-200 和吉利德合作的傳染病項目。這種戰略轉變包括暫停 HB-300 和大多數臨床前研究的開發，以及裁員 30%。重組預計將產生約150萬美元的遣散費和相關費用，由於GMP設施項目的終止，非現金減值費用估計在1000萬至1300萬美元之間。
有用
沒用